Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
| ▸ | TK1 | P04183 | 1/20 | 0.36 |
| ▸ | AGXT | P21549 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 4/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA7 | P43166 | 2/20 | 0.35 |
| ▸ | CA9 | Q16790 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.35 |
| ▸ | TACR1 | P25103 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3334310 | 1.00 | TSHR (0.48) | TSHRIDO1ALOX5TK1AGXT | |
| SCHEMBL5039290 | 0.79 | AOC3 (0.42) | RAB9AKMT2ABCHE | |
| SCHEMBL5038975 | 0.76 | TSHR (0.45) | TSHRIDO1ALOX5TK1AGXT | |
| SCHEMBL27507506 | 0.75 | MAOB (0.46) | TSHRIDO1CA1CA2MEN1 | |
| SCHEMBL29094830 | 0.73 | TP53 (0.41) | TSHRKDM4EMEN1KMT2ABCHE | |
| SCHEMBL5328868 | 0.72 | TSHR (0.41) | TSHRIDO1CA1CA2CA7 | |
| SCHEMBL5046082 | 0.72 | NPC1 (0.37) | TSHRKDM4EMEN1NPC1RAB9A | |
| SCHEMBL5328863 | 0.72 | TSHR (0.41) | TSHRIDO1CA1CA2CA7 | |
| SCHEMBL5035885 | 0.72 | LTA4H (0.46) | TSHRMEN1NPC1RAB9AKMT2A | |
| SCHEMBL1524101 | 0.72 | TSHR (0.67) | TSHRIDO1ALOX5TK1AGXT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8343964-B2 | Indolic derivatives, their preparation processes and their uses in particular as antibacterials | UNIVERSITE JOSEPH FOURIER (FR) | 2013-01-01 | — | — | US | disclosed |
| US-20100144726-A1 | NOVEL INDOLIC DERIVATIVES, THEIR PREPARATION PROCESSES AND THEIR USES IN PARTICULAR AS ANTIBACTERIALS | UNIVERSITE JOSEPH FOURIER (FR) | 2010-06-10 | — | — | US | disclosed |
| EP-1677745-A4 | NITRONE COMPOUNDS PRODRUGS AND PHARMACEUTICAL COMPOSITIONS OF THE SAME TO TREAT HUMAN DISORDERS | RENOVIS INC (US) | 2008-10-22 | — | — | EP | disclosed |
| EP-1677745-A2 | NITRONE COMPOUNDS PRODRUGS AND PHARMACEUTICAL COMPOSITIONS OF THE SAME TO TREAT HUMAN DISORDERS | Renovis, Inc. (US) | 2006-07-12 | — | — | EP | disclosed |
| US-20050192281-A1 | Nitrone compounds, prodrugs and pharmaceuticals compositons of the same to treat human disorders | RENOVIS, INC. | 2005-09-01 | — | — | US | disclosed |
| WO-2005037208-A2 | NITRONE COMPOUNDS PRODRUGS AND PHARMACEUTICAL COMPOSITIONS OF THE SAME TO TREAT HUMAN DISORDERS | RENOVIS, INC. (US) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050192281-A1 | Nitrone compounds, prodrugs and pharmaceuticals compositons of the same to treat human disorders | NLN, NQO1, OPRL1 | TSHR 3020/4885IDO1 236/4885ALOX5 319/4885 |
| US-20100144726-A1 | NOVEL INDOLIC DERIVATIVES, THEIR PREPARATION PROCESSES AND THEIR USES IN PARTICULAR AS ANTIBACTERIALS | GPBAR1, TPH1, GPER1 | TSHR 1579/4885IDO1 32/4885ALOX5 1899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.